Osprey Private Wealth LLC Boosts Stock Holdings in Danaher Co. (NYSE:DHR)

Osprey Private Wealth LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 1.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,250 shares of the conglomerate’s stock after buying an additional 125 shares during the period. Danaher accounts for about 1.8% of Osprey Private Wealth LLC’s portfolio, making the stock its 24th largest holding. Osprey Private Wealth LLC’s holdings in Danaher were worth $2,582,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in DHR. AMF Tjanstepension AB purchased a new stake in shares of Danaher in the third quarter valued at approximately $5,923,000. Czech National Bank grew its position in shares of Danaher by 4.2% in the third quarter. Czech National Bank now owns 130,939 shares of the conglomerate’s stock valued at $36,404,000 after purchasing an additional 5,320 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Danaher by 33.5% in the third quarter. GAMMA Investing LLC now owns 4,480 shares of the conglomerate’s stock valued at $1,246,000 after acquiring an additional 1,125 shares during the last quarter. Diversified Trust Co lifted its holdings in Danaher by 29.6% in the third quarter. Diversified Trust Co now owns 5,649 shares of the conglomerate’s stock valued at $1,571,000 after acquiring an additional 1,289 shares during the last quarter. Finally, Miracle Mile Advisors LLC acquired a new position in Danaher in the third quarter valued at approximately $310,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

NYSE:DHR opened at $215.05 on Wednesday. The firm has a market capitalization of $155.33 billion, a PE ratio of 40.73, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. The business’s fifty day moving average price is $234.93 and its 200 day moving average price is $252.88. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a 12 month low of $210.04 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the company earned $2.09 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 7.77 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.50%. Danaher’s dividend payout ratio (DPR) is 20.45%.

Analyst Ratings Changes

DHR has been the topic of a number of recent analyst reports. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Friday, December 13th. Robert W. Baird decreased their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Jefferies Financial Group decreased their price target on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Barclays decreased their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. decreased their price target on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $278.00.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.